ERBB2 and in situ carcinoma: Two investigators independently evaluated HER2 expression by separately assessing the lower/basal and upper/luminal halves of the urothelium in the study by Gunia et al. [33], yielding significantly different scores in both cases between CIS and non-CIS entities (namely, dysplasia and reactive atypia).